Literature DB >> 3965089

Classification of non-Hodgkin's lymphomas. Reproducibility of major classification systems. NCI non-Hodgkin's Classification Project Writing Committee.

.   

Abstract

An international, multi-institutional, clinical, pathologic study of 1175 cases of non-Hodgkin's lymphoma sponsored by the National Cancer Institute has offered a unique opportunity to investigate issues of reproducibility and agreement in pathologic classification. Teams of experienced hematopathologists reviewed all 1175 cases, with the "experts" utilizing their own classification system and the experienced panelists utilizing all six of the histopathologic classification systems. The fact that 20% of the slides were randomly repeated for a second interpretation allowed assessment of the reproducibility of any one given pathologist. In addition, the agreement between and among pathologists was evaluated. Results of this retrospective study showed that both experts and panelists were able to identify follicular (nodular) or other indolent lymphomas with 95% probability of concurrence between initial and later interpretations. Moreover, individual pathologists agreed with others in identifying and classifying these follicular features with approximately 90% probability of agreement. The reproducibility for individual pathologists, based on the 20% of cases that were randomly repeated, varied from a probability 0.53 to 0.93. Comparisons of intersystem predictability demonstrated that no one system predicted for any of the other systems within any major degree of reliability. This inability to "translate" from one system to another is thought to be a reflection of the problems of both interpathologist agreement and intrapathologist reproducibility. Flaws in study design are discussed and the usage of the working formulation of non-Hodgkin's lymphomas, in addition to classification by traditional schemas, is strongly encouraged.

Entities:  

Mesh:

Year:  1985        PMID: 3965089     DOI: 10.1002/1097-0142(19850101)55:1<91::aid-cncr2820550115>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Application of quantifiable criteria in the Lukes and Collins classification of non-Hodgkin's lymphomas.

Authors:  H Schultz; J Ersbøll
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

2.  Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.

Authors:  Ann S LaCasce; Michelle E Kho; Jonathan W Friedberg; Joyce C Niland; Gregory A Abel; Maria Alma Rodriguez; Myron S Czuczman; Michael M Millenson; Andrew D Zelenetz; Jane C Weeks
Journal:  J Clin Oncol       Date:  2008-09-02       Impact factor: 44.544

Review 3.  Classification of lymphoid neoplasms: the microscope as a tool for disease discovery.

Authors:  Elaine S Jaffe; Nancy Lee Harris; Harald Stein; Peter G Isaacson
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

Review 4.  Mycobiome diversity: high-throughput sequencing and identification of fungi.

Authors:  R Henrik Nilsson; Sten Anslan; Mohammad Bahram; Christian Wurzbacher; Petr Baldrian; Leho Tedersoo
Journal:  Nat Rev Microbiol       Date:  2019-01       Impact factor: 60.633

5.  Clinical medicine and clinical trials.

Authors:  Joel E Tepper
Journal:  Oncologist       Date:  2010

6.  Spontaneous follicular center cell lymphomas of B cell origin in cataract mice.

Authors:  S Hayashi; T Nonoyama; H Miyajima
Journal:  Jpn J Cancer Res       Date:  1992-03

7.  Discrepancies in Lymphoma Diagnosis Over the Years: A 13-Year Experience in a Tertiary Center.

Authors:  Neval Özkaya; Nuray Başsüllü; Ahu Senem Demiröz; Nükhet Tüzüner
Journal:  Turk J Haematol       Date:  2016-12-12       Impact factor: 1.831

8.  Review of Hematopathology Consult Cases: A Two-Year Experience in a Tertiary Referral Center in Lebanon.

Authors:  Sara A J Sinno; Zaher I Chakhachiro; Samer R Nassif
Journal:  Biomed Res Int       Date:  2018-12-30       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.